July 2025 – Page 13 – Talk Bio

Actionable Insights Powered by AI

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

3 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

3 months ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)

Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic

3 months ago talkbio0Tagged Actithera, Andreas Goutopoulos, clinic entry, financing characteristics, Radiopharma, Series

Actithera; radiopharma; Series A; biotech funding; clinic entry; Andreas Goutopoulos; startup financing

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

3 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments

RFK Jr. Cancels USPSTF Meeting Amid Healthcare Groups’ Integrity Concerns

3 months ago talkbio0Tagged CHARGE Syndrome, Congress (U.S. Legislature), expert, Health Policy, meeting cancellation, Preventive Care, RFK Jr., USPSTF

RFK Jr.; USPSTF; meeting cancellation; preventive care; health policy; HHS; Congress; expert panel integrity

Merck Makes $10B Acquisition of Verona Pharma to Bolster Respiratory Portfolio

3 months ago talkbio0Tagged Acquisition, COPD, Drug Industry, Keytruda patent, Merck, Ohtuvayre, Pharma, Respiration Disorders, Verona

Merck; Verona Pharma; acquisition; Ohtuvayre; COPD; respiratory disease; Keytruda patent; biotech; pharmaceutical industry

FDA Approves Updated Dosing for Lilly’s Kisunla to Lower Brain Swelling Risk

3 months ago talkbio0Tagged Alzheimer 's disease, Cerebral Edema, dosing, eli lilly, Kisunla, label update, Neuregulins, Safety, Treatment Protocols, United States Food and Drug Administration

FDA; Kisunla; Eli Lilly; Alzheimer’s disease; dosing regimen; brain swelling; ARIA; safety; label update; TRAILBLAZER-ALZ 6

Rhythm’s Oral MC4R Agonist Bivamelagon Shows Promising Results in Rare Obesity Type

3 months ago talkbio0Tagged Agonist, Bivamelagon, Body mass index procedure, Clinical Trials, Hypothalamic obesity, MC4R protein, human, oral weight loss drug, Rhythm

Rhythm Pharmaceuticals; oral weight-loss drug; bivamelagon; MC4R agonist; Phase 2 trial; hypothalamic obesity; BMI reduction; clinical trial results

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

3 months ago talkbio0Tagged Blood - brain barrier anatomy, Brain Delivery Module, dealmaking, Eledon, Iambic, Neuroscience discipline, Novartis, Revolution Medicines, Sernova, Sironax

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma

3 months ago talkbio0Tagged AAVS1 gene, Alexion, AstraZeneca, Capsid, gene therapy, genomic medicines, Infrequent, JCR, JUST-AAV, Licensing Deal

AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines